Patents by Inventor Pierre Langlade-Demoyen

Pierre Langlade-Demoyen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMS
    Publication number: 20230250175
    Abstract: The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G ?2M-free or ?2M-associated immunosuppressive isoforms respectively.
    Type: Application
    Filed: October 19, 2022
    Publication date: August 10, 2023
    Inventors: Maria LOUSTAU, François ANNA, Pierre LANGLADE DEMOYEN, Julien CAUMARTIN
  • SINGLE-DOMAIN ANTIBODIES DIRECTED AGAINST LILRB2
    Publication number: 20230235050
    Abstract: The present invention relates to single-domain antibodies (sdAbs) directed against Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2), pharmaceutical compositions comprising
    Type: Application
    Filed: September 18, 2020
    Publication date: July 27, 2023
    Applicant: Invectys SAS
    Inventors: Maria LOUSTAU, Lise HUNAULT, Pierre LANGLADE DEMOYEN, Julien CAUMARTIN
  • Anti HLA-G specific antibodies
    Patent number: 11634494
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: April 25, 2023
    Assignee: Invectys SA
    Inventors: Pierre Langlade Demoyen, Thierry Huet, Julien Caumartin, Maria Loustau, Maria Wehbe
  • Chimeric antigen receptors against multiple HLA-G isoforms
    Patent number: 11505608
    Abstract: The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G ?2M-free or ?2M-associated immunosuppressive isoforms respectively.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: November 22, 2022
    Assignee: Invectys SA
    Inventors: Maria Loustau, François Anna, Pierre Langlade Demoyen, Julien Caumartin
  • CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMS
    Publication number: 20220281981
    Abstract: The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G ?2M-free or ?2M-associated immunosuppressive isoforms respectively.
    Type: Application
    Filed: May 9, 2022
    Publication date: September 8, 2022
    Inventors: Maria LOUSTAU, François ANNA, Pierre LANGLADE DEMOYEN, Julien CAUMARTIN
  • ANTI HLA-G SPECIFIC ANTIBODIES
    Publication number: 20220251216
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.
    Type: Application
    Filed: April 25, 2022
    Publication date: August 11, 2022
    Inventors: Pierre LANGLADE DEMOYEN, Thierry HUET, Julien CAUMARTIN, Maria LOUSTAU, Maria WEHBE
  • Recombinant measles vaccine expressing hTERT
    Patent number: 11351246
    Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: June 7, 2022
    Assignees: INVECTYS SAS, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Langlade Demoyen, Frédéric Tangy, Elodie Pliquet
  • Chimeric antigen receptors against multiple HLA-G isoforms
    Patent number: 11325977
    Abstract: The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G ?2M-free or ?2M-associated immunosuppressive isoforms respectively.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: May 10, 2022
    Assignee: Invectys SA
    Inventors: Maria Loustau, François Anna, Pierre Langlade Demoyen, Julien Caumartin
  • Anti HLA-G specific antibodies
    Patent number: 11312774
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: April 26, 2022
    Assignee: Invectys SA
    Inventors: Pierre Langlade Demoyen, Thierry Huet, Julien Caumartin, Maria Loustau, Maria Wehbe
  • ANTI HLA-G SPECIFIC ANTIBODIES
    Publication number: 20220056140
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.
    Type: Application
    Filed: September 3, 2021
    Publication date: February 24, 2022
    Inventors: Pierre LANGLADE DEMOYEN, Thierry HUET, Julien CAUMARTIN, Maria LOUSTAU, Maria WEHBE
  • CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMS
    Publication number: 20210403574
    Abstract: The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G ?2M-free or ?2M-associated immunosuppressive isoforms respectively.
    Type: Application
    Filed: September 10, 2021
    Publication date: December 30, 2021
    Inventors: Maria LOUSTAU, François ANNA, Pierre LANGLADE DEMOYEN, Julien CAUMARTIN
  • METHOD TO ASSESS CAR FUNCTIONALITY
    Publication number: 20210325372
    Abstract: The present invention relates a method for assessing the functionality of a chimeric antigen receptors (CAR) expressing cell. More specifically, this method is based on a trogocytosis process which involves membrane transfer between antigen expressing target cells and antigen specific immune cells.
    Type: Application
    Filed: August 30, 2019
    Publication date: October 21, 2021
    Inventors: Maria LOUSTAU, François ANNA, Pierre LANGLADE DEMOYEN, Julien CAUMARTIN
  • ANTI HLA-G SPECIFIC ANTIBODIES
    Publication number: 20210309748
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.
    Type: Application
    Filed: March 25, 2021
    Publication date: October 7, 2021
    Inventors: Pierre LANGLADE DEMOYEN, Thierry HUET, Julien CAUMARTIN, Maria LOUSTAU, Maria WEHBE
  • Chimeric antigen receptors against multiple HLA-G isoforms
    Patent number: 11117971
    Abstract: The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G ?2M-free or ?2M-associated immunosuppressive isoforms respectively.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: September 14, 2021
    Assignee: Invectys SA
    Inventors: Maria Loustau, François Anna, Pierre Langlade Demoyen, Julien Caumartin
  • Anti HLA-G specific antibodies
    Patent number: 11111302
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: September 7, 2021
    Assignee: Invectys SA
    Inventors: Pierre Langlade Demoyen, Thierry Huet, Julien Caumartin, Maria Loustau, Maria Wehbe
  • POLYEPITOPE CONSTRUCTS FOR USE IN IMMUNOTHERAPY
    Publication number: 20210254098
    Abstract: The present invention relates to DNA expression vector or a mixture of DNA expression vectors which encodes at least two CD4 epitopes of telomerase reverse transcriptase (TERT) and at least one tumor, viral, bacterial, or parasitic CD8 epitope.
    Type: Application
    Filed: April 27, 2021
    Publication date: August 19, 2021
    Inventors: Pierre LANGLADE DEMOYEN, Thierry HUET, Simon WAIN-HOBSON, Anna KOSTRZAK
  • RECOMBINANT MEASLES VACCINE EXPRESSING HTERT
    Publication number: 20210077613
    Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.
    Type: Application
    Filed: May 7, 2018
    Publication date: March 18, 2021
    Applicants: INVECTYS, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre LANGLADE DEMOYEN, Frédéric TANGY, Elodie PLIQUET
  • ANTI HLA-G SPECIFIC ANTIBODIES
    Publication number: 20210054081
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 25, 2021
    Inventors: Pierre LANGLADE DEMOYEN, Thierry HUET, Julien CAUMARTIN, Maria LOUSTAU, Maria WEHBE
  • CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMS
    Publication number: 20210040217
    Abstract: The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G ?2M-free or ?2M-associated immunosuppressive isoforms respectively.
    Type: Application
    Filed: October 22, 2020
    Publication date: February 11, 2021
    Inventors: Maria LOUSTAU, Anna FRANCOIS, Pierre LANGLADE DEMOYEN, Julien CAUMARTIN
  • Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
    Patent number: 10767167
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: September 8, 2020
    Assignees: INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut